## Oscar L Lopez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6485335/publications.pdf

Version: 2024-02-01

312 papers	44,580 citations	86 h-index	198 g-index
329	329	329	39585
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Air pollution and dementia in older adults in the Ginkgo Evaluation of Memory Study. Alzheimer's and Dementia, 2023, 19, 549-559.	0.4	12
2	Revisiting Purine Nucleoside Cholinesterase Inhibitors - An Experimental Glycon Structure/Activity Relationship Study. Medicinal Chemistry, 2023, 19, 263-275.	0.7	1
3	Direct Comparison of the Tau PET Tracers <sup>18</sup> F-Flortaucipir and <sup>18</sup> F-MK-6240 in Human Subjects. Journal of Nuclear Medicine, 2022, 63, 108-116.	2.8	39
4	Neuropsychological, neuropsychiatric, and qualityâ€ofâ€life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. Alzheimer's and Dementia, 2022, 18, 1314-1324.	0.4	17
5	Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate. Brain, 2022, 145, 1992-2007.	3.7	6
6	Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90+. Alzheimer's and Dementia, 2022, , .	0.4	2
7	Psychosis in Alzheimer's Disease Is Associated With Increased Excitatory Neuron Vulnerability and Post-transcriptional Mechanisms Altering Synaptic Protein Levels. Frontiers in Neurology, 2022, 13, 778419.	1.1	3
8	Targeted Lipidomics To Measure Phospholipids and Sphingomyelins in Plasma: A Pilot Study To Understand the Impact of Race/Ethnicity in Alzheimer's Disease. Analytical Chemistry, 2022, 94, 4165-4174.	3.2	5
9	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
10	11C-PiB PET can underestimate brain amyloid- $\hat{l}^2$ burden when cotton wool plaques are numerous. Brain, 2022, 145, 2161-2176.	3.7	8
11	Association of Serum Neurofilament Light Chain Concentration and MRI Findings in Older Adults. Neurology, 2022, 98, .	1.5	9
12	Standardization and diagnostic utility of the Frontal Assessment Battery for healthy people and patients with dementia in the Chilean population. Dementia E Neuropsychologia, 2022, 16, 69-78.	0.3	1
13	Association of Peripheral Lymphocyte Subsets with Cognitive Decline and Dementia: The Cardiovascular Health Study. Journal of Alzheimer's Disease, 2022, 88, 7-15.	1.2	3
14	Pattern of Altered Magnetization Transfer Rate in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-13.	1.2	0
15	Genome-Wide Association Study of Incident Dementia in a Community-Based Sample of Older Subjects. Journal of Alzheimer's Disease, 2022, 88, 787-798.	1.2	2
16	Clinical Progression of Baseline Risk States for Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, , 1-8.	1.2	0
17	Differential Effects of AIDS and Chronic Human Immunodeficiency Virus Infection on Gray Matter Volume. Clinical Infectious Diseases, 2021, 73, e2303-e2310.	2.9	4
18	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Molecular Psychiatry, 2021, 26, 309-321.	4.1	47

#	Article	IF	CITATIONS
19	Estrogen, brain structure, and cognition in p <scp>ostmenopausal</scp> women. Human Brain Mapping, 2021, 42, 24-35.	1.9	27
20	Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma. Journal of Alzheimer's Disease, 2021, 79, 1327-1344.	1.2	16
21	Late-life depression and increased risk of dementia: a longitudinal cohort study. Translational Psychiatry, 2021, 11, 147.	2.4	41
22	Hemostatic factor levels and cognitive decline in older adults: The Cardiovascular Health Study. Journal of Thrombosis and Haemostasis, 2021, 19, 1219-1227.	1.9	3
23	ENGAGE and EMERGE: Truth and consequences?. Alzheimer's and Dementia, 2021, 17, 692-695.	0.4	58
24	Dataset of why inclusion matters for Alzheimer's disease biomarker discovery in plasma. Data in Brief, 2021, 35, 106923.	0.5	1
25	Case-cohort study of plasma phospholipid fatty acid profiles, cognitive function, and risk of dementia: a secondary analysis in the Ginkgo Evaluation of Memory Study. American Journal of Clinical Nutrition, 2021, 114, 154-162.	2.2	7
26	Cerebral Blood Flow Predicts Conversion of Mild Cognitive Impairment into Alzheimer's Disease and Cognitive Decline: An Arterial Spin Labeling Follow-up Study. Journal of Alzheimer's Disease, 2021, 82, 293-305.	1.2	26
27	Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries. Frontiers in Neurology, 2021, 12, 663407.	1.1	10
28	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	4.1	30
29	Association Between the APOE É>2/É>4 Genotype and Alzheimer's Disease and Mild Cognitive Impairment Among African Americans. Journal of Alzheimer's Disease, 2021, 81, 943-948.	1.2	2
30	Peripheral inflammatory biomarkers predict the deposition and progression of amyloid- $\hat{l}^2$ in cognitively unimpaired older adults. Brain, Behavior, and Immunity, 2021, 95, 178-189.	2.0	22
31	Air pollution and plasma amyloid beta: Evidence from the Ginkgo Evaluation of Memory Study. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
32	Association of Thyroid Dysfunction With Cognitive Function. JAMA Internal Medicine, 2021, 181, 1440.	2.6	51
33	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. Brain Sciences, 2021, 11, 1180.	1.1	0
34	Cardiovascular damage phenotypes and all-cause and CVD mortality in older adults. Annals of Epidemiology, 2021, 63, 35-40.	0.9	2
35	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619.	2.8	21
36	Prognostic accuracy for predicting ordinal competing risk outcomes using ROC surfaces. Lifetime Data Analysis, 2021, 28, 1.	0.4	1

#	Article	IF	Citations
37	Clonal Hematopoiesis is Associated with Reduced Risk of Alzheimer's Disease. Blood, 2021, 138, 5-5.	0.6	15
38	Association of low-frequency and rare coding variants with information processing speed. Translational Psychiatry, 2021, 11, 613.	2.4	2
39	Genetic data and cognitively defined late-onset Alzheimer's disease subgroups. Molecular Psychiatry, 2020, 25, 2942-2951.	4.1	57
40	Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 2020, 78, 134-144.	2.6	38
41	High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. Journal of Lipid Research, 2020, 61, 445-454.	2.0	15
42	Sex Differences in the Association Between Pentraxin 3 and Cognitive Decline: The Cardiovascular Health Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1523-1529.	1.7	2
43	Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. Nature Communications, 2020, 11, 4796.	5.8	61
44	Associations of equolâ $\in$ producing status with white matter lesion and amyloidâ $\in$ $\hat{\mathbb{I}}^2$ deposition in cognitively normal elderly Japanese. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12089.	1.8	10
45	Brachial Flow-mediated Dilation and Risk of Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 272-274.	0.6	2
46	Inclusion of African American/Black adults in a pilot brain proteomics study of Alzheimer's disease. Neurobiology of Disease, 2020, 146, 105129.	2.1	18
47	Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. Neurology, 2020, 95, e984-e994.	1.5	14
48	Examining the Causal Mediating Role of Brain Pathology on the Relationship Between Diabetes and Cognitive Impairment: The Cardiovascular Health Study. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 1705-1726.	0.6	4
49	Hippocampal sclerosis, TDPâ€43, and the duration of the symptoms of dementia of AD patients. Annals of Clinical and Translational Neurology, 2020, 7, 1546-1556.	1.7	15
50	Orthostatic hypotension, dizziness, neurology outcomes, and death in older adults. Neurology, 2020, 95, e1941-e1950.	1.5	14
51	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimer's and Dementia, 2020, 16, 1412-1425.	0.4	82
52	Associations of body composition with incident dementia in older adults: Cardiovascular Health Studyâ€Cognition Study. Alzheimer's and Dementia, 2020, 16, 1402-1411.	0.4	13
53	Cerebral small vessel disease genomics and its implications across the lifespan. Nature Communications, 2020, 11, 6285.	5.8	89
54	Whole-Exome Sequencing Analysis of Alzheimer's Disease in Non-APOE*4 Carriers. Journal of Alzheimer's Disease, 2020, 76, 1553-1565.	1.2	18

#	Article	IF	Citations
55	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	6.0	450
56	The roles of study setting, response bias, and personality in subjective memory complaints of cognitively normal older adults. International Psychogeriatrics, 2020, 33, 1-12.	0.6	3
57	A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, 1330-1337.	0.4	19
58	Cerebral Blood Flow Is Associated with Diagnostic Class and Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 1103-1120.	1.2	26
59	Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. Neurobiology of Aging, 2020, 94, 111-120.	1.5	15
60	Twenty-seven-year time trends in dementia incidence in Europe and the United States. Neurology, 2020, 95, e519-e531.	1.5	227
61	Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia. JAMA Network Open, 2020, 3, e209250.	2.8	23
62	The Effect of the <scp><i>APOE ε2ε4</i></scp> Genotype on the Development of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in Nonâ€Latino Whites. Journal of the American Geriatrics Society, 2020, 68, 1044-1049.	1.3	8
63	Relationship of amyloid-β1–42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study. Brain Communications, 2020, 2, fcz038.	1.5	10
64	Alcohol Consumption, Brain Amyloid- $\hat{l}^2$ Deposition, and Brain Structural Integrity Among Older Adults Free of Dementia. Journal of Alzheimer's Disease, 2020, 74, 509-519.	1.2	4
65	Long-term cognitive decline and mortality after carotid endarterectomy. Clinical Neurology and Neurosurgery, 2020, 194, 105823.	0.6	0
66	A genome-wide association study identifies genetic loci associated with specific lobar brain volumes. Communications Biology, 2019, 2, 285.	2.0	27
67	Blood amyloid levels and risk of dementia in the Ginkgo Evaluation of Memory Study (GEMS): A longitudinal analysis. Alzheimer's and Dementia, 2019, 15, 1029-1038.	0.4	14
68	Alcohol Consumption and Risk of Dementia and Cognitive Decline Among Older Adults With or Without Mild Cognitive Impairment. JAMA Network Open, 2019, 2, e1910319.	2.8	102
69	Highâ€dimensional longitudinal classification with the multinomial fused lasso. Statistics in Medicine, 2019, 38, 2184-2205.	0.8	6
70	Preventing disability in older adults with mild cognitive impairment: A Strategy Training intervention study. Contemporary Clinical Trials Communications, 2019, 15, 100368.	0.5	5
71	HIV infection and age effects on striatal structure are additive. Journal of NeuroVirology, 2019, 25, 480-495.	1.0	12
72	Problemâ€solving therapy reduces subjective burden levels in caregivers of family members with mild cognitive impairment or earlyâ€stage dementia: Secondary analysis of a randomized clinical trial. International Journal of Geriatric Psychiatry, 2019, 34, 957-965.	1.3	17

#	Article	IF	Citations
73	Effect of S-equol and Soy Isoflavones on Heart and Brain. Current Cardiology Reviews, 2019, 15, 114-135.	0.6	56
74	Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry. JAMA Network Open, 2019, 2, e191350.	2.8	58
75	Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients. American Journal of Geriatric Psychiatry, 2019, 27, 908-917.	0.6	13
76	Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 61-69.	1.8	63
77	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
78	Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 139-148.	1.0	85
79	Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 515-523.	1.8	4
80	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
81	Spectrum of tau pathologies in Huntington's disease. Laboratory Investigation, 2019, 99, 1068-1077.	1.7	23
82	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	2.1	79
83	Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk. Neurolmage, 2018, 172, 118-129.	2.1	82
84	Practice guideline update summary: Mild cognitive impairment. Neurology, 2018, 90, 126-135.	1.5	1,263
85	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
86	Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology, 2018, 90, e1920-e1928.	1.5	36
87	<i>APOE</i> DNA methylation is altered in Lewy body dementia. Alzheimer's and Dementia, 2018, 14, 889-894.	0.4	17
88	Vascular disease and cerebral amyloid deposition. Neurology, 2018, 90, 635-636.	1.5	6
89	Genetic risk for schizophrenia and psychosis in Alzheimer disease. Molecular Psychiatry, 2018, 23, 963-972.	4.1	55
90	Anxiety symptoms and risk of dementia and mild cognitive impairment in the oldest old women. Aging and Mental Health, 2018, 22, 474-482.	1.5	30

#	Article	IF	CITATIONS
91	Diabetes and Cognitive Decline in Older Adults: The Ginkgo Evaluation of Memory Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 123-130.	1.7	69
92	Amyloid $\hat{l}^2$ Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. JAMA Neurology, 2018, 75, 88.	4.5	33
93	Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. Nature Communications, 2018, 9, 3945.	5.8	31
94	Aortic Stiffness is Associated with Increased Risk of Incident Dementia in Older Adults. Journal of Alzheimer's Disease, 2018, 66, 297-306.	1.2	37
95	Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 542-555.	1.8	10
96	Apolipoproteins and Alzheimer's pathophysiology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 545-553.	1.2	19
97	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	5.8	484
98	Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 413-420.	1.2	9
99	Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of $\hat{Al^2}$ load. NeuroImage: Clinical, 2018, 19, 182-189.	1.4	13
100	Sleep moderates the relationship between amyloid beta and memory recall. Neurobiology of Aging, 2018, 71, 142-148.	1.5	31
101	Scientific Autobiography: On Brain Health and Cognitive Fitness Into the Later Years of Life—Journey of a Behavioral Neurologist of Aging. American Journal of Geriatric Psychiatry, 2018, 26, 1184-1189.	0.6	0
102	Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. American Journal of Psychiatry, 2018, 175, 999-1009.	4.0	25
103	The Relationship of Current Cognitive Activity to Brain Amyloid Burden and Glucose Metabolism. American Journal of Geriatric Psychiatry, 2018, 26, 977-984.	0.6	5
104	Author response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 2018, 91, 373-374.	1.5	25
105	Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes inÂAlzheimer's Disease Patients: AÂMulticenter, Randomized, Controlled Clinical Trial. Journal of Alzheimer's Disease, 2017, 56, 129-143.	1.2	67
106	Physical activity predicts reduced plasma $\langle i \rangle \hat{l}^2 \langle i \rangle$ amyloid in the Cardiovascular Health Study. Annals of Clinical and Translational Neurology, 2017, 4, 284-291.	1.7	30
107	Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology, 2017, 88, 2089-2097.	1.5	117
108	Anxiety symptoms and risk of cognitive decline in older community-dwelling men. International Psychogeriatrics, 2017, 29, 1137-1145.	0.6	32

#	Article	IF	Citations
109	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	4.9	394
110	Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. European Journal of Epidemiology, 2017, 32, 931-938.	2.5	23
111	Associations of fat and muscle tissue with cognitive status in older adults: the AGES-Reykjavik Study. Age and Ageing, 2017, 46, 250-257.	0.7	41
112	Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia. JAMA Neurology, 2017, 74, 1105.	4.5	136
113	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
114	Subclinical Atherosclerosis, Cardiac and Kidney Function, Heart Failure, and Dementia in the Very Elderly. Journal of the American Heart Association, 2017, 6, .	1.6	12
115	Association of Brain Amyloid- $\hat{l}^2$ With Slow Gait in Elderly Individuals Without Dementia. JAMA Neurology, 2017, 74, 82.	4.5	66
116	[O4–07–03]: AMYLOID DEPOSITION AND BRAIN STRUCTURE AS LONGâ€TERM PREDICTORS OF DEMENTIA I COGNITIVELY NORMAL AND MCI INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P1244.	N <sub>0.4</sub>	0
117	Vitamin D and Risk of Neuroimaging Abnormalities. PLoS ONE, 2016, 11, e0154896.	1.1	12
118	Inflammatory Biomarkers and Cognitive Decline: The Ginkgo Evaluation of Memory Study. Journal of the American Geriatrics Society, 2016, 64, 1171-1177.	1.3	16
119	Tau Platelets Correlate with Regional BrainÂAtrophy in Patients with Alzheimer'sÂDisease. Journal of Alzheimer's Disease, 2016, 55, 1595-1603.	1.2	19
120	Vitamin D and Memory Decline: Two Population-Based Prospective Studies. Journal of Alzheimer's Disease, 2016, 50, 1099-1108.	1.2	41
121	Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 921-932.	1.2	77
122	The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. American Journal of Psychiatry, 2016, 173, 543-546.	4.0	279
123	Cardiovascular disease and dementia risk: an ever growing problem in an aging population. Expert Review of Cardiovascular Therapy, 2016, 14, 771-773.	0.6	6
124	Inflammatory Biomarkers Predict Domain-Specific Cognitive Decline in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw155.	1.7	27
125	Slow gait, white matter characteristics, and prior 10-year interleukin-6 levels in older adults. Neurology, 2016, 87, 1993-1999.	1.5	16
126	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213

#	Article	IF	Citations
127	Arguing against the proposed definition changes of PD. Movement Disorders, 2016, 31, 1619-1622.	2.2	55
128	Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease. Molecular and Cellular Proteomics, 2016, 15, 2252-2262.	2.5	26
129	Longitudinal Relationships between Caloric Expenditure and Gray Matter in the Cardiovascular Health Study. Journal of Alzheimer's Disease, 2016, 52, 719-729.	1.2	21
130	Brain Volume as an Integrated Marker for the Risk of Death in a Community-Based Sample: Age Gene/Environment Susceptibility—Reykjavik Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 131-137.	1.7	13
131	Dyadic Analysis of Illness Perceptions Among Persons with Mild Cognitive Impairment and Their Family Members. Gerontologist, The, 2016, 56, 886-895.	2.3	18
132	Subclinical Cardiovascular Disease and Death, Dementia, and Coronary Heart Disease in Patients 80+Years. Journal of the American College of Cardiology, 2016, 67, 1013-1022.	1.2	82
133	Risk of dementia and death in the longâ€term followâ€up of the Pittsburgh Cardiovascular Health Study–Cognition Study. Alzheimer's and Dementia, 2016, 12, 170-183.	0.4	33
134	Global and local ancestry in Africanâ€Americans: Implications for Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 233-243.	0.4	42
135	GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Molecular Psychiatry, 2016, 21, 189-197.	4.1	134
136	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
137	Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease. PLoS Genetics, 2016, 12, e1006327.	1.5	47
138	Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease. Journal of Clinical Psychiatry, 2016, 77, e1564-e1569.	1.1	24
139	Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. NeuroImage: Clinical, 2015, 9, 479-483.	1.4	25
140	Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging. Journal of Alzheimer's Disease, 2015, 49, 723-732.	1.2	45
141	Amyloid- $\hat{l}^2$ Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. Journal of Alzheimer's Disease, 2015, 48, S151-S159.	1.2	80
142	Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 167-178.	1.2	20
143	Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Molecular Psychiatry, 2015, 20, 594-601.	4.1	101
144	More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiology of Aging, 2015, 36, 2443.e21-2443.e26.	1.5	39

#	Article	IF	Citations
145	S4-01-04: Amyloid imaging in the 80+ population and cognitive trajectories (GEMS)., 2015, 11, P257-P258.		О
146	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. Neurobiology of Aging, 2015, 36, 1765.e7-1765.e16.	1.5	82
147	Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53 949). Molecular Psychiatry, 2015, 20, 183-192.	4.1	344
148	Statins and brain integrity in older adults: Secondary analysis ofÂtheÂHealth ABC study. Alzheimer's and Dementia, 2015, 11, 1202-1211.	0.4	14
149	Genome-wide copy-number variation study of psychosis in Alzheimer's disease. Translational Psychiatry, 2015, 5, e574-e574.	2.4	24
150	Cerebral bleed after shunt for normal pressure hydrocephalus with cerebral amyloid angiopathy. Neurology: Clinical Practice, 2015, 5, 263-266.	0.8	3
151	Objective measures of physical activity, white matter integrity and cognitive status in adults over age 80. Behavioural Brain Research, 2015, 284, 51-57.	1.2	55
152	Trajectories of peripheral interleukin-6, structure of the hippocampus, and cognitive impairment over 14Ayears in older adults. Neurobiology of Aging, 2015, 36, 3038-3044.	1.5	21
153	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2015, 14, 804-813.	4.9	91
154	Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. JAMA Neurology, 2015, 72, 1021.	4.5	71
155	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta inÂCognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2015, 23, 985-993.	0.6	112
156	Empirically Derived Trajectories to Dementia Over 15 Years of Follow-up Identified by Using Mixed Membership Models. American Journal of Epidemiology, 2015, 182, 366-374.	1.6	7
157	Relative <sup>11</sup> C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session <sup>15</sup> O-Water and <sup>11</sup> C-PiB PET. Journal of Nuclear Medicine, 2015, 56, 1199-1205.	2.8	62
158	Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults. JAMA - Journal of the American Medical Association, 2015, 314, 781.	3.8	318
159	Fetuin-A and risk of coronary heart disease: A Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies. Atherosclerosis, 2015, 243, 44-52.	0.4	21
160	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
161	Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Biological Psychiatry, 2015, 77, 749-763.	0.7	67
162	Physical activity, body mass index, and brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2015, 36, S194-S202.	1.5	59

#	Article	IF	CITATIONS
163	Genetic Variation in Imprinted Genes is Associated with Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 989-994.	1.2	32
164	Relationship between Systemic and Cerebral Vascular Disease and Brain Structure Integrity in Normal Elderly Individuals. Journal of Alzheimer's Disease, 2015, 44, 319-328.	1.2	15
165	A Rare Duplication on Chromosome $16p11.2$ Is Identified in Patients with Psychosis in Alzheimer's Disease. PLoS ONE, 2014, 9, e111462.	1.1	16
166	Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis. Journal of Alzheimer's Disease, 2014, 39, 759-773.	1.2	46
167	TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. International Psychogeriatrics, 2014, 26, 987-994.	0.6	13
168	ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Molecular Psychiatry, 2014, 19, 682-687.	4.1	62
169	Use of Cardiac Implantable Electronic Devices in Older Adults With Cognitive Impairment. JAMA Internal Medicine, 2014, 174, 1514.	2.6	7
170	Arterial Stiffness and $\hat{I}^2$ -Amyloid Progression in Nondemented Elderly Adults. JAMA Neurology, 2014, 71, 562.	4.5	152
171	Effect of Dementia on the Use of Drugs for Secondary Prevention of Ischemic Heart Disease. Journal of Aging Research, 2014, 2014, 1-8.	0.4	5
172	Physical activity, inflammation, and volume of the aging brain. Neuroscience, 2014, 273, 199-209.	1.1	53
173	Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study. Journal of Psychiatric Research, 2014, 49, 96-101.	1.5	64
174	Effects of memantine treatment on language abilities and functional communication: A review of data. Aphasiology, 2014, 28, 236-257.	1.4	12
175	Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1779.e15-1779.e16.	1.5	28
176	Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs. Alzheimer's and Dementia, 2014, 10, 409-415.	0.4	69
177	Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiology of Aging, 2014, 35, 802-807.	1.5	62
178	Preventing Dementia in Older Cardiovascular Patients. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	3
179	Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 710-717.	1.5	41
180	A genome-wide association meta-analysis of plasma $\hat{A}^2$ peptides concentrations in the elderly. Molecular Psychiatry, 2014, 19, 1326-1335.	4.1	36

#	Article	IF	CITATIONS
181	Genetic Determinants of Disease Progression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 649-655.	1.2	53
182	Regular Fish Consumption and Age-Related Brain Gray Matter Loss. American Journal of Preventive Medicine, 2014, 47, 444-451.	1.6	82
183	Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology, 2014, 83, 1804-1811.	1.5	46
184	Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities. Neurobiology of Aging, 2014, 35, 2021-2028.	1.5	40
185	A Self-Report Risk Index to Predict Occurrence of Dementia in Three Independent Cohorts of Older Adults: The ANU-ADRI. PLoS ONE, 2014, 9, e86141.	1.1	121
186	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
187	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain, 2013, 136, 2510-2526.	3.7	294
188	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
189	Pulmonary Function Impairment May Be an Early Risk Factor for Lateâ€Life Cognitive Impairment. Journal of the American Geriatrics Society, 2013, 61, 79-83.	1.3	47
190	Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimer's and Dementia, 2013, 9, 338-345.	0.4	72
191	Cognitive trajectories associated with $\hat{l}^2$ -amyloid deposition in the oldest-old without dementia. Neurology, 2013, 80, 1378-1384.	1.5	77
192	The Long-Term Effects of Conventional and Atypical Antipsychotics in Patients With Probable Alzheimer's Disease. American Journal of Psychiatry, 2013, 170, 1051-1058.	4.0	110
193	Pulse wave velocity is associated with $\hat{l}^2$ -amyloid deposition in the brains of very elderly adults. Neurology, 2013, 81, 1711-1718.	1.5	156
194	Mild Cognitive Impairment. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 411-424.	0.4	36
195	In vivo assessment of amyloidâ€Î² deposition in nondemented very elderly subjects. Annals of Neurology, 2013, 73, 751-761.	2.8	89
196	A Longitudinal Follow-Up of 550 Mild Cognitive Impairment Patients: Evidence for Large Conversion to Dementia Rates and Detection of Major Risk Factors Involved. Journal of Alzheimer's Disease, 2013, 34, 769-780.	1.2	164
197	Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study–Cognition Study. Neurology, 2012, 79, 1599-1606.	1.5	86
198	Effect of Alzheimer's Disease Risk Genes on Trajectories of Cognitive Function in the Cardiovascular Health Study. American Journal of Psychiatry, 2012, 169, 954-962.	4.0	61

#	Article	IF	CITATIONS
199	Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimer's Disease: Comparison of Efficacy and Effectiveness Studies. Neurodegenerative Diseases, 2012, 10, 170-174.	0.8	22
200	Markers of Cholesterol Metabolism in the Brain Show Stronger Associations with Cerebrovascular Disease than Alzheimer's Disease, Journal of Alzheimer's Disease, 2012, 30, 53-61.	1.2	47
201	Patterns of Compensation and Vulnerability in Normal Subjects at Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S427-S438.	1.2	14
202	White matter lesions and brain gray matter volume in cognitively normal elders. Neurobiology of Aging, 2012, 33, 834.e7-834.e16.	1.5	107
203	Genome-wide association study of Alzheimer's disease with psychotic symptoms. Molecular Psychiatry, 2012, 17, 1316-1327.	4.1	110
204	Dementia and Alzheimer's Disease. , 2012, , 561-582.		4
205	Trajectory of Cognitive Decline as a Predictor of Psychosis in Early Alzheimer Disease in the Cardiovascular Health Study. American Journal of Geriatric Psychiatry, 2011, 19, 160-168.	0.6	57
206	Vascular Contributions to Cognitive Impairment and Dementia. Stroke, 2011, 42, 2672-2713.	1.0	2,989
207	No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiology of Aging, 2011, 32, 555.e9-555.e11.	1.5	18
208	Psychosis in Alzheimer's Disease in the National Alzheimer's Disease Coordinating Center Uniform Data Set: Clinical Correlates and Association with Apolipoprotein E. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	1.1	24
209	Evolution of the diagnostic criteria for degenerative and cognitive disorders. Current Opinion in Neurology, 2011, 24, 532-541.	1.8	45
210	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	9.4	1,676
211	Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease. Trials, 2011, 12, 233.	0.7	5
212	The effects of physical activity, education, and body mass index on the aging brain. Human Brain Mapping, 2011, 32, 1371-1382.	1.9	117
213	Maintenance Treatment of Depression in Old Age. Archives of General Psychiatry, 2011, 68, 51.	13.8	145
214	Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence. European Neurological Journal, 2011, 3, 15-19.	0.0	6
215	The growing burden of Alzheimer's disease. American Journal of Managed Care, 2011, 17 Suppl 13, S339-45.	0.8	21
216	Brain structure and obesity. Human Brain Mapping, 2010, 31, 353-364.	1.9	555

#	Article	IF	Citations
217	Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 303, 1832.	3.8	1,064
218	Initial Experience in Using Continuous Arterial Spin-Labeled MR Imaging for Early Detection of Alzheimer Disease. American Journal of Neuroradiology, 2010, 31, 847-855.	1.2	31
219	Telephone Interview for Cognitive Status. Neuroepidemiology, 2010, 34, 63-64.	1.1	16
220	Physical activity predicts gray matter volume in late adulthood. Neurology, 2010, 75, 1415-1422.	1.5	414
221	Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiology of Aging, 2010, 31, 1326-1339.	1.5	170
222	Predicting cognitive decline in Alzheimer's disease: An integrated analysis. Alzheimer's and Dementia, 2010, 6, 431-439.	0.4	34
223	Age, Alzheimer disease, and brain structure. Neurology, 2009, 73, 1899-1905.	1.5	185
224	Mild Cognitive Impairment and Alzheimer Disease: Patterns of Altered Cerebral Blood Flow at MR Imaging. Radiology, 2009, 250, 856-866.	3.6	336
225	<emph type="ital">Ginkgo biloba</emph> for Preventing Cognitive Decline in Older Adults <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2009, 302, 2663.	3.8	286
226	Amyloid imaging in mild cognitive impairment subtypes. Annals of Neurology, 2009, 65, 557-568.	2.8	309
227	Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 600-607.	0.9	210
228	Depressed Mood is Not a Risk Factor for Incident Dementia in a Community-Based Cohort. American Journal of Geriatric Psychiatry, 2009, 17, 653-663.	0.6	103
229	Identifying mild cognitive impairment at baseline in the Ginkgo Evaluation of Memory (GEM) study. Aging and Mental Health, 2009, 13, 171-182.	1.5	18
230	Patterns of Mild Cognitive Impairment After Treatment of Depression in the Elderly. American Journal of Geriatric Psychiatry, 2009, 17, 308-316.	0.6	96
231	The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. International Psychogeriatrics, 2009, 21, 78.	0.6	57
232	Clinical symptoms in Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 207-216.	1.0	27
233	Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 271-279.	0.4	86
234	Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE $\hat{l}\mu 4$ . Archives of Neurology, 2008, 65, 89-93.	4.9	263

#	Article	lF	Citations
235	Fast 3D fluid registration of brain magnetic resonance images. , 2008, 6916, .		17
236	Abnormal Regional Cerebral Blood Flow in Cognitively Normal Elderly Subjects With Hypertension. Stroke, 2008, 39, 349-354.	1.0	131
237	<emph type="ital">Ginkgo biloba</emph> for Prevention of Dementia <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2008, 300, 2253.	3.8	553
238	Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology, 2008, 70, 1664-1671.	1.5	148
239	Effectiveness and Safety of Donepezil in Hispanic Patients with Alzheimer's Disease: A 12-Week Open-Label Study. Journal of the National Medical Association, 2008, 100, 1350-1358.	0.6	21
240	Incidence of Dementia in Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. Archives of Neurology, 2007, 64, 416.	4.9	144
241	Chapter 2 Alzheimer's Disease. Blue Books of Neurology, 2007, , 33-58.	0.1	2
242	Progression to Dementia in Probable and Possible Mild Cognitive Impairmentâ€"Reply. Archives of Neurology, 2007, 64, 1210.	4.9	1
243	Cerebral Ventricular Changes Associated With Transitions Between Normal Cognitive Function, Mild Cognitive Impairment, and Dementia. Alzheimer Disease and Associated Disorders, 2007, 21, 14-24.	0.6	114
244	Gene-Environment Interactions With Cognition in Late Life and Compression of Morbidity. American Journal of Psychiatry, 2007, 164, 849-852.	4.0	7
245	Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiology of Aging, 2007, 28, 389-397.	1.5	92
246	Acceleration of cerebral ventricular expansion in the Cardiovascular Health Study. Neurobiology of Aging, 2007, 28, 1316-1321.	1.5	24
247	Prediction of psychosis onset in Alzheimer disease: The role of depression symptom severity and the HTR2A T102C polymorphism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1054-1062.	1.1	26
248	Focal Atrophy and Cerebrovascular Disease Increase Dementia Risk among Cognitively Normal Older Adults. Journal of Neuroimaging, 2007, 17, 148-155.	1.0	30
249	Commentary on "Vascular cognitive impairment: Today and tomorrow― , 2006, 2, 200-201.		1
250	Prediction of Psychosis Onset in Alzheimer Disease: The Role of Cognitive Impairment, Depressive Symptoms, and Further Evidence for Psychosis Subtypes. American Journal of Geriatric Psychiatry, 2006, 14, 352-360.	0.6	45
251	Three-dimensional Patterns of Hippocampal Atrophy in Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 97.	4.9	101
252	Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease. Neurology, 2006, 67, 660-665.	1.5	36

#	Article	IF	Citations
253	Neuropsychological characteristics of mild cognitive impairment subgroups. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 159-165.	0.9	150
254	A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1116-1121.	0.9	175
255	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology, 2005, 65, 1863-1872.	1.5	4,604
256	Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition. Journal of the American Geriatrics Society, 2005, 53, 83-87.	1.3	111
257	RESPONSE LETTER TO DR. THOMAS FINUCANE. Journal of the American Geriatrics Society, 2005, 53, 1831-1833.	1.3	2
258	Dementia and Alzheimer's Disease Incidence in Relationship to Cardiovascular Disease in the Cardiovascular Health Study Cohort. Journal of the American Geriatrics Society, 2005, 53, 1101-1107.	1.3	425
259	Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology, 2005, 64, 1539-1547.	1.5	99
260	Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology, 2005, 64, 1548-1552.	1.5	166
261	Statin Use and the Risk of Incident Dementia. Archives of Neurology, 2005, 62, 1047.	4.9	261
262	Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase, 2005, 11, 65-71.	0.2	84
263	Differential Cortical Atrophy in Subgroups of Mild Cognitive Impairment. Archives of Neurology, 2005, 62, 1393.	4.9	183
264	Functional neuroimaging indicators of successful executive control in the oldest old. NeuroImage, 2005, 28, 881-889.	2.1	43
265	Event-related functional magnetic resonance imaging investigation of executive control in very old individuals with mild cognitive impairment. Biological Psychiatry, 2005, 57, 761-767.	0.7	71
266	Survival following dementia onset: Alzheimer's disease and vascular dementia. Journal of the Neurological Sciences, 2005, 229-230, 43-49.	0.3	120
267	Neuropathologic Correlates of Late-Onset Major Depression. Neuropsychopharmacology, 2004, 29, 2242-2250.	2.8	96
268	Incidence and Prevalence of Dementia in the Cardiovascular Health Study. Journal of the American Geriatrics Society, 2004, 52, 195-204.	1.3	367
269	Diagnosis, risk factors, and treatment of vascular dementia. Current Neurology and Neuroscience Reports, 2004, 4, 358-367.	2.0	4
270	Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. European Journal of Neurology, 2004, 11, 97-102.	1.7	39

#	Article	IF	Citations
271	Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. Archives of Neurology, 2003, 60, 1385.	4.9	605
272	Risk Factors for Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. Archives of Neurology, 2003, 60, 1394.	4.9	406
273	Evaluation of Dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology, 2003, 22, 1-12.	1.1	215
274	Risk Factors for Dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology, 2003, 22, 13-22.	1.1	267
275	Psychiatric Symptoms Vary With the Severity of Dementia in Probable Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 346-353.	0.9	206
276	Patterns of Change in the Treatment of Psychiatric Symptoms in Patients With Probable Alzheimer's Disease From 1983 to 2000. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 67-73.	0.9	10
277	Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology, 2002, 58, 907-911.	1.5	94
278	Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2002, 288, 1475.	3.8	1,676
279	Research Evaluation and Prospective Diagnosis of Dementia With Lewy Bodies. Archives of Neurology, 2002, 59, 43.	4.9	137
280	Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 310-314.	0.9	212
281	The Psychotic Phenomenon in Probable Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 50-55.	0.9	64
282	Psychotic Symptoms in Alzheimer's Disease Are Not Associated With More Severe Neuropathologic Features. International Psychogeriatrics, 2000, 12, 547-558.	0.6	56
283	Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies. Neurology, 2000, 54, 1780-1787.	1.5	68
284	Predictors of progression in patients with AD and Lewy bodies. Neurology, 2000, 54, 1774-1779.	1.5	76
285	Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology, 2000, 55, 1854-1862.	1.5	150
286	Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 233-239.	0.9	1,342
287	Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology, 2000, 55, 1863-1869.	1.5	112
288	Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology, 1999, 53, 1292-1292.	1.5	224

#	Article	IF	Citations
289	Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease. Archives of Neurology, 1999, 56, 1266.	4.9	173
290	Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1999, 12, 184-92.	0.4	34
291	Extrapyramidal Signs in Patients With Probable Alzheimer Disease. Archives of Neurology, 1997, 54, 969-975.	4.9	119
292	EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Neurology, 1997, 48, 1521-1525.	1.5	57
293	Psychiatric correlates of MR deep white matter lesions in probable Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 1997, 9, 246-250.	0.9	22
294	The apolipoprotein E ϵ4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology, 1997, 49, 794-797.	1.5	65
295	Creutzfeldt-Jakob disease with features of obsessive-compulsive disorder and anorexia nervosa: the role of cortical-subcortical systems. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1997, 10, 120-4.	0.4	4
296	Development of Subtle Neurological Signs after Systemic Illness in HIV-infected Individuals. European Neurology, 1996, 36, 71-75.	0.6	4
297	Methodological considerations in estimating speed of cognitive operations. Journal of the International Neuropsychological Society, 1995, 1, 3-9.	1.2	7
298	Computed Tomographybut Not Magnetic Resonance ImagingIdentified Periventricular White-Matter Lesions Predict Symptomatic Cerebrovascular Disease in Probable Alzheimer's Disease. Archives of Neurology, 1995, 52, 659-664.	4.9	91
299	The Natural History of Alzheimer's Disease. Archives of Neurology, 1994, 51, 585.	4.9	359
300	Speech motor control disorder after HIV infection. Neurology, 1994, 44, 2187-2187.	1.5	10
301	Reliability of NINDSâ€AIREN clinical criteria for the diagnosis of vascular dementia. Neurology, 1994, 44, 1240-1240.	1.5	92
302	Ideomotor and ideational apraxia in alzheimer's disease. International Journal of Geriatric Psychiatry, 1993, 8, 413-417.	1.3	32
303	Neuropsychiatric Correlates of Cerebral White-Matter Radiolucencies in Probable Alzheimer's Disease. Archives of Neurology, 1992, 49, 828-834.	4.9	58
304	Material-specific memory loss in probable Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1177-1181.	0.9	17
305	Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects Stroke, 1992, 23, 1078-1083.	1.0	40
306	Neurological complications after liver retransplantation. Hepatology, 1992, 16, 162-166.	3.6	29

#	Article	lF	CITATIONS
307	Alzheimer's disease with delusions and hallucinations. Neurology, 1991, 41, 906-906.	1.5	132
308	Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. Transplantation Proceedings, 1991, 23, 3181-2.	0.3	23
309	Alzheimer's disease and depression: neuropsychological impairment and progression of the illness. American Journal of Psychiatry, 1990, 147, 855-860.	4.0	79
310	Reliability of NINCDSâ€ADRDA clinical criteria for the diagnosis of Alzheimer's disease. Neurology, 1990, 40, 1517-1517.	1.5	71
311	Diagnosis of dementia. Neurology, 1989, 39, 76-76.	1.5	162
312	Mechanism of the Effect of Constant Infusion of Epinephrine on Blood Pressure, Heart Rate and Arterial Hematocrit in Normal and Sympathectomized-Splanchnicectomized Dogs. Archives Internationales De Physiologie Et De Biochimie, 1960, 68, 785-792.	0.2	2